Clinical Trial Update: Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of Nadolol for smoking cessation in patients with chronic cough with or without airflow obstruction. Results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• Nadolol (Nadolol)

Snippet

Sponsor: Invion, Inc. | Conditions: Smoking Cessation | Phase 2 | Status: COMPLETED | Results posted: 2016-10-25